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Purpose: To understand the patient characteristics associated with treatment choice at the first 
treatment intensification for type 2 diabetes.
Patients and methods: This is a noninterventional study, using UK electronic primary care 
records from the Clinical Practice Research Datalink. We included adults treated with met-
formin monotherapy between January 2000 and July 2017. The outcome of interest was the 
drug prescribed at first intensification between 2014 and 2017. We used multinomial logistic 
regression to calculate the ORs for associations between the drugs and patient characteristics.
Results: In total, 14,146 people started treatment with an intensification drug. Younger people 
were substantially more likely to be prescribed sodium-glucose co-transporter-2 inhibitors 
(SGLT2is), than sulfonylureas (SUs): OR for SGLT2i prescription for those aged <30 years was 
2.47 (95% CI 1.39–4.39) compared with those aged 60–70 years. Both overweight and obesity 
were associated with greater odds of being prescribed dipeptidyl peptidase-4 inhibitor (DPP4i) 
or SGLT2i. People of non-white ethnicity were less likely to be prescribed SGLT2i or DPP4i: 
compared with white patients, the OR of being prescribed SGLT2i among South Asians is 0.60 
(95% CI 0.42–0.85), and for black people, the OR is 0.54 (95% CI 0.30–0.97). Lower socioeco-
nomic status was also independently associated with reduced odds of being prescribed SGLT2is.
Conclusion: Both clinical and demographic factors are associated with prescribing at the first 
stage of treatment intensification, with older and non-white people less likely to receive new 
antidiabetic treatments. Our results suggest that the selection of treatment options used at the 
first stage of treatment intensification for type 2 diabetes is not driven by clinical need alone.
Keywords: drug prescriptions, diabetes mellitus, type 2, hypoglycemic agents, primary health 
care, practice patterns, physicians
Introduction
Current UK and international guidelines endorse metformin as the first-line treatment 
for most patients with type 2 diabetes.1–4 In the UK, if further treatment is needed, 
National Institute for Health and Care Excellence (NICE) guidance suggests the addi-
tion of sulfonylureas (SUs), sodium-glucose co-transporter-2 inhibitors (SGLT2is), 
dipeptidyl peptidase-4 inhibitors (DPP4is), and thiazolidinediones (TZD) that have 
different risk profiles and restrictions.1 The most commonly prescribed drug options 
are SUs, DPP4is, and SGLT2is.5 Two of these drug classes have been available only 
recently, DPP4is since 2007 and SGLT2is since 2013.1–4 Another drug class recom-
mended by NICE at this stage of treatment are the TZDs; however, prescribing of TZDs 
has fallen substantially over recent years and is now rarely used at the first stage of 
treatment intensification in the UK.5,6
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At present, guidelines do not present evidence of superior-
ity for any of these first-stage intensification drug choices. The 
factors influencing prescribing are not known but may include 
reported adverse events, growing familiarity with new agents, 
evidence from clinical trials, and influence of pharmaceutical 
companies.6,7 Therefore, our aim was to examine the patient 
characteristics associated with the class of drug prescribed 
within primary care in the United Kingdom National Health 
Service (NHS). To ensure comparability and to reflect recent 
changes in practice, we focused only on commonly used drug 
classes at the first stage of drug intensification for type 2 dia-
betes: SUs, DPP4is, and SGLT2is, between 2014 and 2017.
Materials and methods
study design and setting
This noninterventional study used data from the UK Clinical 
Research Datalink (CPRD), a database of pseudonymized 
primary care health data broadly representative of the UK 
population. CPRD data include demographic and lifestyle 
factors, prescribing records, clinical diagnoses test records, 
and referrals to secondary care. Data are regularly audited to 
ensure quality.8 In the UK, most people with type 2 diabetes 
are managed in primary care with specialist input only for 
those with complications or very poor glycemic control.1
Participants, exposures, and outcomes
We identified all individuals aged 18 years and over. Although 
type 2 diabetes is typically associated with people over the age 
of 40 years, we chose to include younger patients since the 
age of diagnosis is decreasing over time, and earlier onset is 
associated with poorer patient outcomes.9,10 We included only 
patients registered at the practice for 12 months without treat-
ment for type 2 diabetes in order to restrict the cohort to new 
users of type 2 diabetes drugs, and to limit inclusion of patients 
with type 1 diabetes mellitus. We excluded women with type 
2 diabetes and a history of pregnancy within 12 months of 
potential inclusion as prescribing guidelines recommend dif-
ferent drug regimens for pregnant and breastfeeding women.11
To be eligible, individuals must have initiated treatment 
with metformin monotherapy between 2000 and 2017. Met-
formin is the only drug recommended by NICE as a first-line 
drug treatment for type 2 diabetes unless contraindicated, 
usually for patients with estimated glomerular filtration rate 
(eGFR) below 30 mL/min/1.73 m2.1,12
Outcomes
We investigated the drug prescribed at the first stage of 
intensification as our study outcome and focused on three 
classes of drug recommended by clinical guidelines: SU, 
DPP4i, and SGLT2i. TZDs are now infrequently prescribed 
for new users, so we did not investigate this class of drug as 
an outcome.5 As SGLT2is only became available recently, we 
limited the period to individuals who commenced treatment 
after 2013.5 Insulin is not recommended at the first stage of 
drug intensification so a prescription for insulin may suggest 
a change of diagnosis to type 1 diabetes mellitus, or very 
poor glycemic control. We therefore did not include it as an 
outcome but provide a descriptive analysis of individuals 
prescribed insulin in the Supplementary files. Intensification 
of treatment was defined as prescriptions for type 2 diabe-
tes drugs other than metformin after the day of metformin 
initiation. To minimize misclassification from individuals 
switching drug regimens rather than intensifying treatment, 
we required that a further prescription for metformin was 
issued within 60 days of the first-stage intensification drug 
prescription (Figure 1).
Descriptive variables and covariates
We defined characteristics that we considered may influence 
prescribing choice based on clinical knowledge of type 2 
diabetes, current treatment guidelines, and recommendations 
for individual drugs. We defined these covariates as those 
Metformin monotherapy
Example therapy record showing temporal changes in prescribing indicating intensification
First stage of intensification
Further metformin indicates
intensification rather than switching
Prescription issued for new
antidiabetic drug
Prescribing data:
Interpretation:
Where:
= Index drug: second type 2 diabetes drug, = Metformin
Figure 1 Diagram of identification of individuals at the first stage of intensification of treatment for type 2 diabetes from prescribing records.
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recorded prior to the day the first-stage intensification drug 
was prescribed. For the regression analysis, we considered 
age, sex, body mass index (BMI), ethnicity,13 socioeco-
nomic status, smoking, hemoglobin A1c (HbA1c), eGFR,14 
albumin:creatinine ratio (ACR), indicators of microvascular 
disease, and number of days taking metformin prior to change. 
For all biochemical variables, we included only the last record 
of each covariate in the patient record prior to drug intensifica-
tion, as we considered this was most likely to influence the pre-
scribing clinician at the point of changing treatment. Comorbid 
conditions, cardiovascular disease (CVD), retinopathy,15 prior 
amputations,16,17 diagnoses for neuropathy,18 proteinuric kidney 
disease, heart failure,19,20 and blindness16,20 were defined as 
present if they were recorded in the medical record on or prior 
to the date of drug intensification. We defined drug exposures 
(ACEI/ARB or statins) as any prescription in the year before 
baseline. Patient-level socioeconomic status was assigned 
with quintiles of index of multiple deprivation (IMD) scores 
that were collated in 2015 as the most recent available data.21
For HbA1c test results, all units were converted to mmol/
mol.1 We excluded values less than 20 mmol/mol (4.0%), or 
greater than 200 mmol/mol (20.4%) as invalid. Results older 
than 540 days were classed as “missing” since they were 
unlikely to represent current glycemic control. We classified 
HbA1c into three groups: ≤53 mmol/mol (7%), 54–74 mmol/
mol, and ≥75 mmol/mol (9%) to fit with NICE intensification 
target guidance (guidance recommends a target of 53 mmol/
mol with insulin if HbA1c rises to 75 mmol/mol).
We calculated eGFR using the last serum creatinine result 
within 2 years. We assumed all creatinine measures were 
isotope-dilution mass spectrometry (IDMS)-standardized 
and calculated eGFR using the Chronic Kidney Disease 
Epidemiology Collaboration equation (CKD-EPI) equation.14 
We excluded ethnicity from the estimate of eGFR as General 
Practitioners (GPs) receive unadjusted eGFRs in laboratory 
reports. We grouped eGFR results as analogous to CKD stage: 
0 to <60 mL/min/1.73 m2, 60 to <90 mL/min/1.73 m2, and 
≥90 mL/min/1.73 m2.
To classify proteinuria, we used diagnostic codes for pro-
teinuric kidney disease and continuous measures of ACR. We 
considered patients to have ACR above the normal range if 
ACR test records had a positive qualifier, or where the value 
was greater than 3 mg/mmol. We created a count variable 
of microvascular disease markers that included a positive 
ACR test result, a diagnosis of retinopathy, a diagnosis of 
neuropathy, or a diagnosis of proteinuric kidney disease.22 
To calculate the daily dose of metformin prior to treatment 
change, we used the last metformin prescription prior to 
treatment change and calculated daily dose as the strength 
prescribed multiplied by the number provided each day. We 
included calendar year, split into 6 monthly periods, as a 
covariate to account for prescribing trends in the UK.5 All 
codes used in this analysis are publicly available on the EHR 
data compass website: http://datacompass.lshtm.ac.uk/692/.
statistical analysis
We describe the patients prescribed each drug (SU, DPP4i, 
SGLT2i) at first intensification according to clinical, demo-
graphic, and lifestyle factors. We then used multinomial 
logistic regression modeling to better understand the relation-
ships between drug usage and baseline covariates.23 The OR 
for the explanatory variables denotes the association between 
each variable and each drug class at first-stage intensification 
compared with SU (baseline treatment).
The aim of the multinomial models is not to predict drug 
choice, but to identify which variables might be important to 
clinicians prescribing drugs for first-stage intensification. There-
fore, we did not aim to find the most parsimonious model but 
drew conclusions from a model with as many relevant covari-
ates as possible while ensuring the model would converge.24 
A priori, we defined a wide range of factors that we expected 
to be important to clinical decision-making, including patient 
demographic information, clinical measures, comorbidities, and 
lifestyle measures. We examined variables with strong collinear-
ity and selected the variables for inclusion that were most valid 
given the data available. For example, we chose retinopathy as 
a marker of microvascular disease as a sensitive and validated 
measure that is well screened for in primary care,15 and CVD 
as a marker of macrovascular disease that is well recorded.25 We 
found low numbers of people with reduced kidney function, so 
we used wide eGFR classes to avoid zero-count cells.
To handle missing data, we used multiple imputation with 
chained equations under the assumption of data being missing 
at random (MAR).26 We generated 40 imputed datasets. We 
used predictive mean matching to model continuous variables 
to better account for non-normality than linear regression: 
imputed values were drawn from the nearest ten non-missing 
observations.27 We modeled categorical variables using mul-
tinomial logistic regression and ordered categorical variables 
using ordinal logistic regression. For missingness in continuous 
variables, HbA1c, BMI, and eGFR, we imputed the variables 
on the continuous scale and then converted to categorical 
variables after imputation. The imputation models included all 
covariates in the analysis model, as well as auxiliary variables 
including dementia, heart failure, and blindness diagnoses.
Data extraction and processing of CPRD data were com-
pleted in Stata MP (version 14). All data analysis has been 
completed using Stata MP 14 and R version 3.4.1.
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sensitivity analyses
Patient-level IMD data are only available for practices in Eng-
land, effectively excluding patients in other countries in the 
UK. Therefore, for our primary analysis, we did not include 
IMD to maximize the representativeness of the findings. In 
our first sensitivity analysis, we repeated the primary model 
for England, including patient-level IMD data to explore the 
impact of this on treatment intensification.
In addition, to examine the sensitivity of our results to the 
assumptions made, we conducted further sensitivity analyses. 
If the patient was censored or died in the 60 days after an 
alternate drug was prescribed, it is not known whether further 
metformin therapy was intended by the GP, and therefore these 
individuals could be mistakenly excluded as drug “switchers”. 
Therefore, in a sensitivity analysis, we included all patients 
who died in this period. Finally, retinopathy represents only 
one microvascular complication associated with type 2 diabe-
tes but multiple complications may independently influence 
prescribing. Therefore, we repeated the primary analysis, 
replacing retinopathy with a count of microvascular disease 
markers including a positive ACR test result, diagnosis of 
retinopathy, neuropathy, or proteinuric kidney disease.
Post hoc analyses
We observed a strong calendar time interaction in the logis-
tic regression. We therefore repeated the analysis for each 
individual year 2014–2016 (excluding time as a covariate) 
and compared ORs of interest using forest plots.
Ethical and scientific approval
The research protocol was approved by the Independent 
Scientific Advisory Committee (ISAC) of the Medicines & 
Healthcare products Regulatory Agency Database Research 
(protocol number 16_267). The protocol was made available 
to journal reviewers. This study was also approved by the 
London School of Hygiene and Tropical Medicine Ethics 
Committee, reference 11923.
Data availability
All codes used in this analysis are publicly available on 
the EHR data compass website: http://datacompass.lshtm.
ac.uk/692/; no further data sharing is possible.
Results
We identified 307,554 people who started antidiabetic treat-
ment, between 2000 and 2017, of whom 280,241 people 
were aged 18 years and over, with no recent evidence of 
pregnancy. Of these, 204,238 (73%) initiated treatment 
with metformin monotherapy and 38,739 people received 
SU monotherapy (14%). Of those starting treatment with 
metformin monotherapy, we identified 79,941 (39%) that 
intensified treatment with any further antidiabetic drug. We 
then restricted this group to 14,149 individuals who intensi-
fied treatment between 2014 and 2017 to reflect only con-
temporary prescribing decisions. In our selected cohort, 44% 
(6,294/14,149) received SU, 37% (5,285/14,149) received 
DPP4i, 11% (1,488/14,149) received SGLT2i, and 8% 
(1,082/14,149) received insulin or other combinations (Table 
S1). In keeping with our decision to focus on SUs, DPP4i, and 
SGLT2is, only 2% (290/14,149) of the cohort were prescribed 
TZDs between 2014 and 2017. Full inclusions and exclusions 
are presented in the flowchart in Figure 2.
Start type 2 diabetes drug
n=307,554
No evidence of pregnancy
within 365 days
Initiated treatment with
metformin monotherapy
n=204,238
Intensified treatment
First stage intensification
between January 1, 2014
and July 31, 2017
n=14,149
Outside of period of
interest
n=65,792
Switched treatment
No therapy changes
Initiated treatment on other
therapy
Other options include:
Evidence of pregnancy or
aged <18 years
n=27,313
SU=38,739
met and SU=11,742
insulin=6,771
Stayed on metformin
n=98,890
No metformin in 60 days
after new drug class added
n=25,407
Metformin monotherapy
intensified
Metformin in 60 days after
new drug class added
n=79,941
Further drug added to treatment
n=105,348
Aged 18 years and over
n=280,241
Between January 1, 2000
and July 31, 2017
Marked acceptable by CPRD
12 months of follow-up prior
to first prescription
n=76,003
Figure 2 Flow diagram showing the creation of the study population and reasons 
for exclusion.
Abbreviation: CPrD, UK Clinical research Datalink.
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Table 1 Patient demographic and lifestyle factors, according to first-stage intensification drug prescribing
SU
N=6,294
Freq (%)a
DPP4i
N=5,285
Freq (%)a
SGLT2i
N=1,488
Freq (%)a
age category (years) <30 40 (0.6) 37 (0.7) 22 (1.5)
30–39 224 (3.6) 168 (3.2) 71 (4.8)
40–49 960 (15.3) 735 (13.9) 309 (20.8)
50–59 1,719 (27.3) 1,442 (27.3) 554 (37.2)
60–69 1,749 (27.8) 1,541 (29.2) 417 (28)
70–79 1,140 (18.1) 1,010 (19.1) 106 (7.1)
≥80 462 (7.3) 352 (6.7) 9 (0.6)
gender Female 2,561 (40.7) 2,093 (39.6) 614 (41.3)
BMi Underweight/normal 742 (12) 411 (7.9) 33 (2.2)
Overweight 1,970 (31.9) 1,488 (28.6) 236 (16)
Obese 3,465 (56.1) 3,307 (63.5) 1,205 (81.8)
Missing from complete cohort 117 (1.9) 79 (1.5) 14 (0.9)
Ethnicity White 3,348 (84.3) 2,826 (89.2) 736 (92)
south asian 351 (8.8) 197 (6.2) 39 (4.9)
Black 166 (4.2) 82 (2.6) 13 (1.6)
Other 87 (2.2) 48 (1.5) 9 (1.1)
Mixed 18 (0.5) 16 (0.5) n<5
Missing from complete cohort 2,324 (36.9) 2,116 (40) 688 (46.2)
Patient-level index of 1 lEasT deprived 593 (17.1) 491 (19) 130 (20.7)
multiple deprivation 2 634 (18.3) 473 (18.3) 132 (21.1)
3 705 (20.4) 516 (20) 147 (23.4)
4 802 (23.2) 520 (20.1) 120 (19.1)
5 MOsT deprived 729 (21.1) 581 (22.5) 98 (15.6)
Missing from complete cohort 2,831 (45) 2,704 (51.2) 861 (57.9)
alcohol status nondrinker 1,000 (16.5) 669 (13.1) 171 (12)
Ex-drinker 879 (14.5) 757 (14.8) 207 (14.5)
Current drinker 4,178 (69.1) 3,699 (72.2) 1,052 (73.6)
Missing from complete cohort 237 (3.8) 160 (3) 58 (3.9)
smoking status nonsmoker 2,386 (38) 1,968 (37.3) 589 (39.6)
Current 1,041 (16.6) 813 (15.4) 238 (16)
Ex-smoker 2,854 (45.4) 2,501 (47.3) 660 (44.4)
Missing from complete cohort 13 (0.2) n<5 n<5c
Days since first 
metformin prescription
Mean (sD) 1,182 (1,103) 1,320 (1,105) 1,137 (1,023)
Dose of previous 
metformin prescription 
(mg/day)
Mean (sD) 1,675 (525) 1,742 (484) 1,712 (470)
Missing from complete cohort 2,165 (34) 1,757 (33) 529 (36)
hba1c (mmol/mol) Mean (sD) 80 (21) 73 (16) 76 (18)
<53 (7%)b 182 (4.5) 146 (4.3) 34 (3.9)
53–74 1,864 (45.7) 2,087 (61.5) 444 (51.4)
>75 (9%) 2,030 (49.6) 1,164 (34.3) 386 (44.7)
Missing from complete cohort 2,218 (35) 1,888 (36) 625 (42)
egFr (ml/min/1.73 m2) Mean (sD) 87 (19) 85 (19) 94 (15)
egFr category <60 448 (10.7) 378 (11) 11 (1.2)
(ml/min/1.73 m2) 60–89 1,694 (40.4) 1,457 (42.4) 314 (35.6)
≥90 2,051 (48.9) 1,605 (46.7) 558 (63.2)
Missing from complete cohort 2,101 (33.4%) 1,845 (34.9%) 605 (40.7%)
Proteinuric renal 
disease
159 (2.5) 101 (1.9) 23 (1.5)
raised aCr 828 (28.9) 611 (24.9) 157 (24.9)
Missing from complete cohort 3,431 (54.5) 2,836 (53.7) 858 (57.7)
(Continued)
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Baseline characteristics of patients 
at point of type 2 diabetes drug 
intensification 2014–2017
Patient demographic and lifestyle factors for patients pre-
scribed SUs, DPP4is, and SGLT2is are shown in Table 1. 
Details of patients prescribed insulin or other drug combi-
nations are given in Table S2. The mean age of individuals 
intensifying treatment was 60 years, mean BMI was 33 kg/
m2, and mean eGFR was 87 mL/min/1.73 m2. Individuals 
prescribed SGLT2is were younger, had higher BMIs, a higher 
representation of white people, and fewer people classed as 
more deprived. The DPP4i group had a higher proportion of 
obese people and white people compared with the SU group. 
Of the clinical factors, people prescribed SGLT2is had less 
impaired kidney function compared with people receiving SUs 
and DPP4i (Table 1). The prevalence of neuropathy, blindness, 
heart failure, dementia, and proteinuria was low, and similar, 
across the drug classes. The SGLT2i group had the lowest 
prevalence of CVD (10%) vs 14% in the SU and DPP4i groups.
Multinomial logistic regression
The results of the primary multinomial regression analysis 
are presented in Table 2. Age was associated with prescrib-
ing choice, with younger people substantially more likely 
to be prescribed SGLT2is than SUs. The OR for SGLT2i 
prescription for those aged <30 years was 2.47 (95% CI 
1.39–4.39), compared to those aged 60–70 years, and there 
was a trend towards SU prescribing as age increases. SUs 
were more commonly prescribed for people with very poor 
glycemic control: among people with HbA1c >75, the OR 
for DPP4i prescription was 0.70 (95% CI 0.56–0.88) and 
that for SGLT2is prescription was 0.76 (95% CI 0.52–1.12) 
compared with that for SU prescription. For people with an 
eGFR >90 mL/min/1.73 m2, the odds of receiving SGLT2is 
was 6.72 (95% CI 3.71–12.20) times greater than someone 
with an eGFR <60 mL/min/1.73 m2. The presence of micro-
vascular  and macrovascular diseases was not associated with 
drug prescribing but both being overweight and obese were 
associated with greater odds of being prescribed both DPP4is 
and SGLT2is. Compared with white patients, the odds of 
being prescribed SGLT2i among South Asians was 0.60 (95% 
CI 0.42–0.85) and for black people the OR was 0.54 (95% 
CI 0.30–0.97). The odds of receiving DPP4i was also lower 
for South Asian and black people, 0.71 (95% CI 0.58–0.87) 
and 0.69 (95% CI 0.51–0.95), respectively. In the sensitivity 
analysis also including socioeconomic status, people from 
the two most deprived groups were also less likely to be 
prescribed SGLT2is (eg, OR 0.59 [95% CI 0.44–0.80] for 
the lowest fifth of IMD compared with the highest) while the 
findings for ethnicity were unchanged (Table S3). As we have 
shown previously, prescribing of DPP4i and SGLT2i drugs 
is increasing rapidly over time.5
Table 1 (Continued)
SU
N=6,294
Freq (%)a
DPP4i
N=5,285
Freq (%)a
SGLT2i
N=1,488
Freq (%)a
neuropathy 408 (6.5) 326 (6.2) 70 (4.7)
amputation 51 (0.8) 31 (0.6) 10 (0.7)
retinopathy 1,061 (16.9) 1,018 (19.3) 227 (15.3)
Blindness 41 (0.7) 42 (0.8) n<5
>1 sign of 
microvascular disease
2,073 (32.9) 1,721 (32.6) 416 (28)
systolic BP (mmhg) Mean (sD) 132 (14) 133 (14) 134 (14)
Missing from complete cohort 20 (0.3) 11 (0.2) n<5
CVD 878 (13.9) 744 (14.1) 150 (10.1)
heart failure 103 (1.6) 57 (1.1) 14 (0.9)
aCEi or arB 
prescription
3,342 (53.1) 2,973 (56.3) 828 (55.6)
statin prescription 4,558 (72.4) 4,127 (78.1) 1,085 (72.9)
Notes: numbers are n (%) unless otherwise stated. aUnless otherwise specified; % are of non-missing values, where missing categories are provided, percentage indicates 
percentage from the entire cohort. bhba1c % represents hba1c group according to the national glycohemoglobin standardization Program percentage. cFrequencies below 
five not stated as per Independent Scientific Advisory Committee for MHRA Database Research policy.
Abbreviations: aCEi, angiotensin-converting-enzyme inhibitor; aCr, albumin:creatinine ratio; arB, angiotensin ii receptor blockers; BMi, body mass index; CVD, 
cardiovascular disease; BP, blood pressure; DPP4i, dipeptidyl peptidase-4 inhibitors; hba1c, hemoglobin a1c; sglT2i, sodium-glucose co-transporter-2 inhibitors; sU, 
sulfonylurea; eGFR, estimated glomerular filtration rate.
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Table 2 Fully adjusted Ors (95% Cis) for prescription of DPP4i or sglT2i compared with sUs
Variable SU, Ref DPP4i, OR (95% CI) SGLT2i, OR (95% CI)
N= 6,294 5,285 1,488
age, years
<30 1 1.37 (0.85–2.19) 2.47 (1.39–4.39)
30≤40 1 1.02 (0.82–1.28) 1.33 (0.97–1.82)
40≤50 1 0.98 (0.86–1.11) 1.27 (1.05–1.53)
50≤60 1 0.98 (0.88–1.08) 1.22 (1.04–1.42)
60≤70 1 1 1
70≤80 1 0.96 (0.86–1.08) 0.48 (0.37–0.60)
80 + 1 0.89 (0.75–1.06) 0.15 (0.07–0.29)
gender
Male 1 1 1
Female 1 0.92 (0.85–0.99) 0.99 (0.87–1.12)
hba1c (mmol/mol)
≤53 1 1 1
53–75 1 1.34 (1.07–1.67) 1.12 (0.77–1.63)
>75 1 0.70 (0.56–0.88) 0.76 (0.52–1.12)
egFr (ml/min/1.73 m2)
<60 1 1 1
60–89 1 1.05 (0.90–1.23) 5.86 (3.25–10.58)
>90 1 1.01 (0.86–1.18) 6.72 (3.71–12.20)
Time taking metformin (years)
<1 1 1 1
1 to <3 1 1.27 (1.14–1.40) 1.40 (1.19–1.64)
>3 1 1.31 (1.18–1.44) 1.23 (1.05–1.44)
Cardiovascular disease (CVD)
no CVD 1 1 1
CVD diagnosis 1 0.95 (0.85–1.06) 0.95 (0.77–1.16)
retinopathy
no retinopathy 1 1 1
retinopathy diagnosis 1 1.09 (0.99–1.21) 1.02 (0.86–1.21)
BMi (kg/m2)
normal/underweight 1 1 1
Overweight 1 1.30 (1.12–1.50) 2.22 (1.51–3.25)
Obese 1 1.70 (1.48–1.96) 5.61 (3.90–8.09)
smoking status
none 1 1 1
Ex 1 0.99 (0.90–1.08) 1.00 (0.87–1.15)
Current 1 0.94 (0.84–1.06) 0.81 (0.67–0.97)
Ethnicity
White 1 1 1
south asian 1 0.71 (0.58–0.87) 0.60 (0.42–0.85)
Black 1 0.69 (0.51–0.95) 0.54 (0.30–0.97)
Other 1 0.77 (0.52–1.14) 0.86 (0.39–1.88)
Mixed 1 1.14 (0.48–2.72) 2.08 (0.60–7.29)
Calendar time
Early 2014 1 1 1
late 2014 1 1.14 (1.00–1.29) 1.80 (1.38–2.36)
Early 2015 1 1.36 (1.20–1.53) 2.62 (2.04–3.37)
late 2015 1 1.58 (1.38–1.80) 3.87 (3.01–4.98)
Early 2016 1 2.00 (1.75–2.28) 5.67 (4.42–7.27)
late 2016 1 2.16 (1.86–2.51) 7.91 (6.13–10.20)
Early 2017 1 2.43 (2.06–2.86) 11.02 (8.46–14.36)
Note: results of primary analysis, using multinomial logistic regression with multiple imputation to account for missing data.
Abbreviations: BMi, body mass index; DPP4i, dipeptidyl peptidase-4 inhibitors; hba1c, hemoglobin a1c; sglT2i, sodium-glucose co-transporter-2 inhibitors; sU, 
sulfonylurea; eGFR, estimated glomerular filtration rate.
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Taking a complete case analysis approach to the model, 
or including individuals who were censored or died in the 
60 days after prescribing of the intensification  treatment 
for type 2 diabetes, produced no material differences from 
the primary analysis (Table S4). Redefining microvascular 
disease as a count of disease indicators also had no effect on 
the results (data not shown).
Post hoc analyses
Comparison of ORs for ethnicity for each individual year 
2014–2016 (Figure S1) showed that for both South Asian and 
black people, the OR for receiving either SGLT2i or DPP4i 
was below 1.0 in every year, though for black patients the 
point estimate moves closer to 1.0 over time.
Discussion
We have identified clinical and nonclinical patient factors 
associated with drug prescribing between 2014 and 2017, a 
period when prescribing of the new drug classes, DPP4is and 
SGLT2is, rapidly increased.5 Compared with SUs, SGLT2is 
were more commonly prescribed for younger people, for 
people who are overweight and obese, and for people who 
are white and of higher socioeconomic status. Findings for 
DPP4is are similar, although less marked. SUs are more com-
monly prescribed for patients with very poor diabetic control.
To our knowledge, this is the first analysis of factors 
associated with prescribing choice for the new type 2 diabetes 
drugs in the UK. Our findings reflect contemporary data, col-
lected from a large primary care cohort from January 2000 
to July 2017. We have identified patients starting additional 
treatments at a similar stage in their disease course, enabling 
direct comparability. However, there are limitations to this 
analysis. First, we may have misclassified some patients 
with type 1 diabetes, and as SGLT2is are used off-label as 
an adjunct therapy, this could in part explain our findings of 
an association with prescribing for the youngest patients. 
However, we excluded patients who were prescribed insulin at 
intensification, and required that metformin was re-prescribed 
after drug intensification, so any degree of misclassification 
is likely to be minimal. Second, drug prescribing may be 
influenced by local prescribing guidance such as preap-
proval restrictions issued by clinical-commissioning groups 
(CCGs).28 In turn, CCGs may have varying proportions of 
residents of different ethnicities, so this again may influence 
our findings related to ethnicity and, similarly, to socioeco-
nomic status. Restrictions related to maintaining anonymity 
of the data limit this level of data analysis. Third, we used 
prescribing data collected from primary care and we do not 
know which prescriptions were initiated in secondary care or 
specialist community care. Individuals intensified in special-
ist care environments may be more likely to receive newer 
drug options, which their GP then continues in primary care. 
Therefore, factors leading to inequity of access to new medi-
cations may occur by variation in who is referred to secondary 
care but we could not address this in our analysis. Finally, 
due to low numbers, we did not examine the characteristics 
associated with prescribing of TZDs, although these are a 
comparable choice in current prescribing guidance. Follow-
ing a number of issues including concern about increased 
risk of heart failure and the 2011 MHRA warning of bladder 
cancer risk associated with use of pioglitazone, the TZDs have 
been infrequently prescribed for new users.5,29,30
Of the clinical factors assessed, some of the associations are 
expected. DPP4is are widely accepted to be weight neutral, and 
SGLT2is may aid weight loss, whereas SUs are associated with 
weight gain.2 This may in part explain the independent associa-
tion of being overweight and obese with being prescribed the 
new drugs. We found no SGLT2i prescriptions used in people 
with eGFR <45 mL/min/1.73 m2. This suggests that prescribing 
of SGLT2is is aligned with clinical guidelines and prescribing 
information which restrict SGLT2i prescribing when kidney 
function is low.31 SUs are also prescribed to the patients with 
the poorest glycemic control. This may reflect NICE guidance 
that recommends SUs for patients with symptomatic hypergly-
cemia, or clinicians may perceive that SUs are more effective 
at reducing HbA1c compared with DPP4is and SGLT2is.1,32
Our findings that age, ethnicity, and levels of deprivation 
are associated with choice of treatment are in line with other 
evidence regarding factors that influence prescribing of new 
drugs.33 Younger patients are known to receive newer drugs 
more, perhaps driven by patient information and expectations, 
or by concern that older patients are more likely to experience 
side effects. However, SUs may not be the most appropriate 
treatment choice for older people, given their higher risks 
for hypoglycemia.33–36 Globally, higher income patients often 
receive newer and more expensive drugs due to their ability 
to pay more for treatment.33 However, in our study, all indi-
viduals are under the care of the NHS, and hence the ability 
to pay should have no bearing on prescribing, yet level of 
deprivation is still an independent predictor of drug choice. 
South Asian and black people received newer drug options 
(DPP4is and SGLT2is) less often than white people. Dispar-
ity in diabetes treatment by ethnicity is well established.37 
However, our finding that this extends to prescribing of new 
treatments is novel. The reasons for these differences are 
likely to be complex and could include patient awareness of 
Clinical Epidemiology 2018:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1647
Patterns of oral diabetes medication usage
new drug choices, language barriers, or practice-level dif-
ferences which we were unable to investigate.
An additional finding of our study is the marked dif-
ferences between the characteristics of people prescribed 
SGLT2i in routine clinical use compared with randomized 
trials. The mean age of participants prescribed SGLT2i in our 
study was 55 years compared with 63.2 years in CANVAS 
and 63.1 years in EMPA-REG.38,39 In addition, 68% of people 
in CANVAS randomized to SGLT2i had a prior history of 
CVD, compared with 10% of people with coded CVD who 
received SGLT2i in routine care in our study. The reason for 
the preferential prescribing of these drugs to younger people 
without ischemic heart disease in routine clinical care, despite 
the evidence base generated among people with CVD or high 
cardiovascular risk, is unclear.
This study demonstrates that where there is a choice 
between well-established and more novel treatments for 
type 2 diabetes, both clinical and nonclinical factors are 
associated with prescribing. These include age, ethnicity, 
and socioeconomic status, suggesting there is disparity in 
care unrelated to clinical need. The patient characteristics 
of those taking the newer drugs vary markedly from those 
studied in clinical trials. The impact of these factors on the 
clinical outcomes of patients with type 2 diabetes in a diverse 
population is not yet understood.
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